{
    "clinical_study": {
        "@rank": "53728", 
        "arm_group": {
            "arm_group_label": "Brexpiprazole", 
            "arm_group_type": "Experimental", 
            "description": "Up to 3 mg/day, once daily dose, tablets, orally"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy and safety of flexibly dosed\n      adjunctive brexpiprazole treatment in subjects with major depressive disorder  and anxiety\n      symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor\n      (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response."
        }, 
        "brief_title": "Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Major Depressive Disorder", 
            "Anxiety"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anxiety Disorders", 
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main Inclusion Criteria:\n\n          -  Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by\n             the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text\n             Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric\n             Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation.\n\n          -  Have a treatment history of an inadequate ADT response to at least 1 ADT (but not >\n             3) for the current episode.\n\n          -  Have received a single, trial-approved, SSRI or SNRI at an adequate dose for\n\n             \u2265 6 weeks prior to screening.\n\n          -  Are 18 to 65 years old at the time of consent (inclusive, and outpatients only).\n\n          -  Have a Hamilton Depression Rating Scale (HAM-D)-17-item Total Score \u2265 18 at screening\n             and baseline.\n\n          -  Have a Hamilton Anxiety Rating Scale (HAM-A) Total Score \u2265 20 at screening and\n             baseline.\n\n        Main Exclusion Criteria:\n\n        Subjects with any of the following current Axis I DSM-IV-TR diagnoses:\n\n          -  delirium\n\n          -  dementia\n\n          -  amnestic\n\n          -  other cognitive disorders\n\n          -  schizophrenia\n\n          -  schizoaffective disorder\n\n          -  other psychotic disorders\n\n          -  bipolar I disorder,\n\n          -  bipolar II disorder\n\n          -  bipolar disorder not otherwise specified (NOS)\n\n          -  eating disorders\n\n          -  anorexia nervosa\n\n          -  bulimia\n\n          -  obsessive compulsive disorder\n\n          -  post-traumatic stress disorder\n\n        Subjects with any of the following current Axis II DSM-IV-TR diagnoses:\n\n          -  borderline, antisocial\n\n          -  paranoid\n\n          -  schizoid\n\n          -  schizotypal\n\n          -  histrionic personality disorders\n\n          -  mental retardation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013531", 
            "org_study_id": "331-13-002"
        }, 
        "intervention": {
            "arm_group_label": "Brexpiprazole", 
            "description": "Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally", 
            "intervention_name": "Brexpiprazole", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "schizophrenia", 
            "Major depressive disorder", 
            "Anxiety Symptoms", 
            "Mental Disorders", 
            "Psychotic Disorders", 
            "emotional withdrawal", 
            "antipsychotic"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tuscon", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85712"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Garden Grove", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92845"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92056"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Temecula", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92591"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32607"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32256"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33145"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lafayette", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "47905"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21208"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02131"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haverhill", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01830"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester Hills", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48307"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10168"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Staten Island", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10305"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salem", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97301"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Allentown", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18104"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arlington", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76012"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woodstock", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05091"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23230"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MADRS Total Score change from baseline to Week 6", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013531"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "CGI-S score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "CGI-I score at Week 6.", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "MADRS response rate, where response is defined as  \u2265 50% reduction in respective total scores from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "MADRS remission rate, where remission is defined as MADRS Total Score \u2264 10 and 50% reduction in MADRS Total Score from baseline to Week 6.", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "HAM-D-17 Total Score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "HAM-A Total Score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "SDS 3-item mean score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "MGH-CPFQ Total Score change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "KSQ change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "Go/No-Go task change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "Delay Discounting task-MCQ scores change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "Delay Discounting task-EDT scores change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "BIS-11 change from baseline to Week 6", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }
        ], 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}